A US subsidiary of a mid-sized pharma company in Asia has a robust pipeline of antibody-based and small molecule therapeutics. The firm is currently seeking strategic partnerships involving next-gen technology platforms and novel targets and molecules in the fields of oncology, autoimmune, metabolic, cardiovascular, and other disease areas with unmet medical needs. As one of the leaders in the field of antibody-drug conjugates (ADCs), there is particular interest in partnering with early-stage biotechs that are developing first-in-class antibodies.
The firm is primarily interested in licensing or co-developing antibody-based therapeutics, including those with novel targets, structures/designs, conjugation chemistries, and linker-payload strategies.
The firm has no specific requirements for the company and management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment